Daniel Haymann is an attorney with a leading Swiss law firm. His main area of practice is in corporate and commercial law with a focus on private equity and venture capital transactions as well as in international commercial arbitration, mostly in the commodity trading and medical cannabis industries. He established the first dedicated cannabis practice in Switzerland and advises investors, start-ups, and vertically integrated companies in the cannabis industry along the value chain. Prior to embarking on a second career as an attorney, Daniel gained over 12 years of experience in the trading, mining, energy, and related industries based out of Switzerland, Singapore, and Hong Kong working for multinational corporations as a trader and in managerial positions. He earned a Master of Laws from the University of Zurich and an MBA from the Hong Kong University of Science & Technology.
Daniel has experience in the following areas:
Acquisition finance, Arbitration, Banking and finance, Business Development, Commercial, Commercial (general), Commodities, Company set-up / secretarial, Corporate, Corporate (general), Corporate and commercial (contentious), Disputes / litigation, Disputes / litigation (general), Due diligence, Emerging markets (finance), Financial Management, Financial services, Investment funds, Joint ventures, M&A deals (large / premium), M&A deals (mid-market), M&A deals (small / domestic), Operations, Personal / private client, Private equity, Small claims / disputes (personal), Trade finance
Daniel has previously helped clients in the following industries:
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.